{"id":78678,"date":"2022-11-02T10:39:09","date_gmt":"2022-11-02T09:39:09","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/"},"modified":"2022-11-02T15:39:21","modified_gmt":"2022-11-02T14:39:21","slug":"syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/","title":{"rendered":"Syna Therapeutics signs an exclusive license agreement with Intas to commercialise biosimilar LB-0702"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.pcb.ub.edu\/en\/empresa\/syna-therapeutics\/\" target=\"_blank\" rel=\"noopener\">Syna Therapeutics<\/a>, a joint venture of\u00a0<a href=\"https:\/\/reigjofre.com\/en\/\" target=\"_blank\" rel=\"noopener\">Reig Jofre<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.pcb.ub.edu\/en\/empresa\/leanbiopro\/\" target=\"_blank\" rel=\"noopener\">Leanbio<\/a>, based in the Barcelona Science Park, signed a global licensing deal with Intas Pharmaceuticals to commercialise its\u00a0biosimilar drug LB-0702\u00a0to treat pathologies in the field of haematology.<\/strong><\/p>\n<p>Under the terms of the agreement, Intas have been granted exclusive license rights to commercialise LB-0702 worldwide, and Syna will develop, manufacture and supply LB-0702 to Intas and its affiliates. <a href=\"https:\/\/www.accord-healthcare.com\/es\/\" target=\"_blank\" rel=\"noopener\">Accord Healthcare<\/a>,\u00a0Inta\u2019s subsidiary, one of the key players in the global biosimilars market, has a\u00a0sales and distribution networks in 85 countries.<\/p>\n<p>Syna will begin clinical trials for LB-0702 in 2023 with support from its partners Leanbio and Reig Jofre. Utilising the\u00a0<a href=\"https:\/\/www.leanbiopro.com\/3\/\" target=\"_blank\" rel=\"noopener\">technology platforms of Leanbio<\/a>\u00a0coupled with the technology production expertise of Reig Jofre at its new manufacturing plant in Barcelona (Spain) purposed for sterile injectables and lyophilised biopharmaceutical products.<\/p>\n<p>\u201cSigning this deal is one of Syna\u2019s most important milestones since the company was founded in 2018, and it confirms the pharmaceutical industry and healthcare systems\u2019 growing interest in\u00a0biosimilar drugs,\u201d notes Dr <strong>Andreu Soldevila<\/strong>, co-founder and CEO of Syna. \u201cWe are delighted with this agreement with Intas because we believe biosimilar LB-0702 will have a very positive impact to healthcare systems. The subsidiary Accord Healthcare is the ideal partner to commercialise our biosimilar in global markets\u201d says <strong>Soldevila<\/strong>.<\/p>\n<p><strong>Binish Chudgar<\/strong>, vice chairman and canaging director of Intas, commented, \u201cwe are pleased to announce this agreement with Syna. This agreement sets out Accord Healthcare to file for global rights to this critical drug and is in line with our long-term strategy, reinforcing our commitment\u00a0to improving access to high-quality biosimilar drugs\u00a0for patients globally.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Syna Therapeutics, a joint venture of\u00a0Reig Jofre\u00a0and\u00a0Leanbio, based in the Barcelona Science Park, signed a global licensing deal with Intas Pharmaceuticals to commercialise its\u00a0biosimilar drug LB-0702\u00a0to treat pathologies in the&#8230;<\/p>\n","protected":false},"author":14,"featured_media":78661,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-78678","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Syna Therapeutics signs an exclusive license agreement with Intas to commercialise biosimilar LB-0702 - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syna Therapeutics signs an exclusive license agreement with Intas to commercialise biosimilar LB-0702 - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Syna Therapeutics, a joint venture of\u00a0Reig Jofre\u00a0and\u00a0Leanbio, based in the Barcelona Science Park, signed a global licensing deal with Intas Pharmaceuticals to commercialise its\u00a0biosimilar drug LB-0702\u00a0to treat pathologies in the...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-02T09:39:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-02T14:39:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/11\/SynaTherapeutics.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Syna Therapeutics signs an exclusive license agreement with Intas to commercialise biosimilar LB-0702\",\"datePublished\":\"2022-11-02T09:39:09+00:00\",\"dateModified\":\"2022-11-02T14:39:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\\\/\"},\"wordCount\":286,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/11\\\/SynaTherapeutics.jpg\",\"articleSection\":[\"COMPANIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\\\/\",\"name\":\"Syna Therapeutics signs an exclusive license agreement with Intas to commercialise biosimilar LB-0702 - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/11\\\/SynaTherapeutics.jpg\",\"datePublished\":\"2022-11-02T09:39:09+00:00\",\"dateModified\":\"2022-11-02T14:39:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/11\\\/SynaTherapeutics.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/11\\\/SynaTherapeutics.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syna Therapeutics signs an exclusive license agreement with Intas to commercialise biosimilar LB-0702\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Syna Therapeutics signs an exclusive license agreement with Intas to commercialise biosimilar LB-0702 - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/","og_locale":"en_US","og_type":"article","og_title":"Syna Therapeutics signs an exclusive license agreement with Intas to commercialise biosimilar LB-0702 - Parc Cient\u00edfic de Barcelona","og_description":"Syna Therapeutics, a joint venture of\u00a0Reig Jofre\u00a0and\u00a0Leanbio, based in the Barcelona Science Park, signed a global licensing deal with Intas Pharmaceuticals to commercialise its\u00a0biosimilar drug LB-0702\u00a0to treat pathologies in the...","og_url":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2022-11-02T09:39:09+00:00","article_modified_time":"2022-11-02T14:39:21+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/11\/SynaTherapeutics.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Syna Therapeutics signs an exclusive license agreement with Intas to commercialise biosimilar LB-0702","datePublished":"2022-11-02T09:39:09+00:00","dateModified":"2022-11-02T14:39:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/"},"wordCount":286,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/11\/SynaTherapeutics.jpg","articleSection":["COMPANIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/","url":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/","name":"Syna Therapeutics signs an exclusive license agreement with Intas to commercialise biosimilar LB-0702 - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/11\/SynaTherapeutics.jpg","datePublished":"2022-11-02T09:39:09+00:00","dateModified":"2022-11-02T14:39:21+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/11\/SynaTherapeutics.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/11\/SynaTherapeutics.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/syna-therapeutics-signs-an-exclusive-license-agreement-with-intas-to-commercialise-biosimilar-lb-0702\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Syna Therapeutics signs an exclusive license agreement with Intas to commercialise biosimilar LB-0702"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/78678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=78678"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/78678\/revisions"}],"predecessor-version":[{"id":78743,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/78678\/revisions\/78743"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/78661"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=78678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=78678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=78678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}